Search clinical trials for: NXL103

Total 22 results

Axoltis Pharma
ACT4ALS network

Not yet recruiting

ALS Phase II Study of NX210c (SEALS)

Amyotrophic Lateral Sclerosis

France
Axoltis Pharma
Centre for Human Drug Research, Netherlands

Recruiting

MAD Study of NX210c (CHDR2235)

Healthy Elderly

Netherlands
Forest Laboratories

Completed

Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections

Urinary Tract Infections

Russian Federation, Bulgaria, Poland, Germany, United States, Lebanon, Turkey
Novexel Inc

Completed

Comparative Study of NXL103 Versus Comparator in Adults With Community Acquired Pneumonia

Community Acquired Pneumonia

Germany, Chile, Peru, Estonia, Croatia, South Africa, Poland, Romania, Ukraine
ABL Bio, Inc.

Recruiting

A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors

Advanced Solid Tumor

Korea, Republic of
Novexel Inc

Completed

Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Acute Bacterial Skin and Skin Structure Infections

United States, Guatemala
Institut du Cancer de Montpellier - Val d'Aurelle

Completed

Safety and Efficacity of NFL101 as Tobacco Therapy (CESTO)

Smoking

France
Shanghai General Hospital, Shanghai Jiao Tong University...
Innostellar Biotherapeutics

Recruiting

Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS)

X-linked Retinoschisis

China
Starmab biologics（Shanghai）Co,.ltd

Active, not recruiting

A Phase I Study of XJ103 in Chinese Healthy Subjects

Pneumococcal Disease

China
Beijing Northland Biotech. Co., Ltd.

Recruiting

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1)

Ischemia | Peripheral Vascular Disease | Arterial Occlusive Disease | Ulcers

China
Beijing Northland Biotech. Co., Ltd.

Completed

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003CLI-II)

Ischemia | Peripheral Vascular Disease | Arterial Occlusive Disease | Ulcers

China
Guangzhou Excelmab Inc.

Recruiting

Safety and Efficacy of EX103 in Subjects With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

CD20-positive Non-Hodgkin Lymphoma

China
Beijing Northland Biotech. Co., Ltd.

Recruiting

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-2)

Ischemia | Peripheral Vascular Disease | Arterial Occlusive Disease | Ulcers

China
Pfizer

Completed

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]NXL104

Healthy

United Kingdom
Pfizer

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects

Healthy Male and Female Japanese Volunteers

United States
Beijing Northland Biotech. Co., Ltd.

Recruiting

Angiogenesis and Blood Perfusion Effect of HGF Gene Therapy in PAD Patients

Peripheral Artery Disease

China
Pfizer

Completed

Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections

Complicated Urinary Tract Infection

United States, Lebanon, Jordan
Gyongyi Szabo
National Institute on Alcohol Abuse and Alcoholism (NIAAA); The Cleveland Clinic and other collaborators

Withdrawn

A Pilot, Dose Escalating Study on VLX103 in Moderate Alcoholic Steatohepatitis

Hepatic Steatosis

United States
Oncozyme Pharma Inc.

Completed

A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma

Hepatocellular Carcinoma

Canada
Pfizer

Completed

Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections

Complicated Intra-abdominal Infections

United States, Lebanon, France, Romania, Bulgaria, India, Poland, Russian Federation
Pfizer

Completed

A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers

Healthy Male Volunteers

United States
Exelixis

Active, not recruiting

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Triple Negative Breast Cancer | Epithelial Ovarian Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor Positive Breast Carcinoma | Neoplasm Malignant

United States

Search clinical trials for: NXL103

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations